Fate Therapeutics (NASDAQ: FATE) — Company Overview, News & Financial Data
Fate Therapeutics develops programmed cellular immunotherapies for cancer, leveraging iPSC technology for innovative treatments.
Fate Therapeutics
Fate Therapeutics (NASDAQ:FATE) is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. Their cutting-edge approaches leverage induced pluripotent stem cell (iPSC) technology to produce natural killer (NK) and T-cell therapies aimed at transforming the treatment landscape for patients battling these severe diseases. With a pipeline featuring multiple projects in various stages of development, the company focuses on advancing its cell-based treatments through clinical trials, aiming to offer innovative solutions that can improve patient outcomes. A key objective for Fate Therapeutics is to harness the power of their proprietary technology to lead the way in iPSC-derived, off-the-shelf cell-based cancer immunotherapy, providing hope and potential new therapies for patients worldwide.
Snapshot
Operations
Products and/or services of Fate Therapeutics
- iPSC-derived NK and T-cell therapies targeting cancer.
- iPSC-derived CAR NK-cell therapy for B-cell lymphoma.
- Partnership with ONO Pharmaceutical for immuno-oncology cell therapy.
- Development of FT516, an engineered NK cell therapy for hematologic malignancies.
- FT538, an advanced NK cell therapy for solid tumors and hematologic malignancies.
Fate Therapeutics executive team
- Bahram ValamehrPresident, CEO & Director
- Kamal AdawiCFO & Treasurer
- Cindy R. TahlChief Legal & Compliance Officer and Corporate Secretary
- Jessica FrancisSenior Vice President of Human Resources & Operations
- Martin HoskingHead of Research
- Tunde BabalolaSenior Vice President of Technical Operations & Quality
- Ryan DouglasSenior Director of Investor Relations & Business Development
- Andrew HenrySenior Vice President of Clinical Operations
- Yu CaiHead of Intellectual Property & Assistant General Counsel
Key financials
Reported results for Fate Therapeutics, in USD.
- Market cap
- 240.8M
- Revenue (TTM)
- 6.5M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 6.6M | -147.7M | -136.3M | |
| 13.6M | -210.3M | -186.3M | |
| 63.5M | -190.5M | -160.9M | |
| 96.3M | -308.4M | -255.1M |